Compare EOG Resources Inc (EOG) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
EOG Resources Inc vs State Street SPDR S&P Biotech ETF — how do they compare? EOG Resources Inc trades at $149.36 (market cap $77.90B), while State Street SPDR S&P Biotech ETF trades at $153.1 (market cap $10.11B). The key difference: EOG Resources Inc is far larger — about 7.7× State Street SPDR S&P Biotech ETF's market cap, and EOG Resources Inc pays a 2.75% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold EOG Resources Inc for 59 Days and State Street SPDR S&P Biotech ETF for 37 Days on average.
| EOG | XBI | |
|---|---|---|
Market Cap | $77.90B | $10.11B |
Volume | 2,930,386 | 12,903,266 |
Sector | Energy | Broad Market / Factor |
52-Week High | $153.74 | $169.55 |
52-Week Low | $101.78 | $104.99 |
Typical Hold Time | 59 Days | 37 Days |
Enterprise Value | $81.24B | — |
Dividend Yield | 2.75% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EOG Resources trades at $144.21, showing minimal daily movement with a slight decline of 0.05%. The stock maintains strong technical momentum with bullish moving averages and sits near pivot point resistance at $145. Fundamentally, EOG demonstrates robust profitability with 25.81% net income margin and attractive valuation metrics including a P/E of 11.56. Recent quarters show consistent earnings beats, with Q2 2026 EPS of $5.07 exceeding expectations. The company maintains solid cash flow generation despite increased capital expenditures.
EOG presents a compelling investment case with strong operational execution, disciplined capital allocation, and shareholder returns through dividends. Analyst consensus remains bullish with 59% buy ratings and $164.77 price target representing 14% upside. Key risks include oil price volatility and execution challenges in maintaining production growth. The combination of value pricing, consistent earnings performance, and positive technical momentum supports a constructive outlook for patient investors.
XBI trades at $153.34, up 2.07% today, but faces bearish technical signals with 17 sell indicators versus 4 buys. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from recent M&A activity and positive clinical trial catalysts. Current price sits near resistance at $154, with support at $147.
Biotech sector optimism is growing with cancer vaccine breakthroughs and improved capital access, though XBI's 0.35% expense ratio is higher than broader healthcare ETFs. Key risks include sector volatility and regulatory uncertainty, while analyst consensus remains neutral with 100% hold rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About EOG Resources Inc
EOG Resources is an oil and gas producer with acreage in several U.S. shale plays, including the Permian Basin, the Eagle Ford, and the Bakken. At the end of 2021, it reported net proved reserves of 3.7 billion barrels of oil equivalent. Net production averaged 829 thousand barrels of oil equivalent per day in 2021 at a ratio of 72% oil and natural gas liquids and 28% natural gas.
Read more on EOG →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
